2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

9:00AM-11:00AM: Abstract Number: 106

Rheumatology Fellows Teaching in a Consult Setting: Pilot Project at Two Training Hospitals

Education Poster

9:00AM-11:00AM: Abstract Number: 101

Rime (Reporter-Interpreter-Moderator-Educator) Evaluation Tool to Assess Fellows in Rheumatology

Education Poster

9:00AM-11:00AM: Abstract Number: 317

Risk Factors for Blood Transfusions Following Total Joint Arthroplasty in Patients with Rheumatoid Arthritis

ARHP Orthopedics, Low Back Pain and Rehabilitation Poster

9:00AM-11:00AM: Abstract Number: 717

Risk Factors for Neuropsychiatric Systemic Lupus Erythematosus and Its Recurrence

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 819

Risks of Non-Cardiovascular Corticosteroid Related Adverse Events and Cancer in Giant Cell Arteritis: A French Population-Based Cohort Study

Vasculitis Poster I: Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 649

Role of Eicosanoids As Biomarkers in Psoriatic Arthritis

Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster I

9:00AM-11:00AM: Abstract Number: 651

Role of Mir-21-5p As a Potential Biomarker of Psoriatic Arthritis and Response to Treatment

Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster I

9:00AM-11:00AM: Abstract Number: 752

Role of the Six-Minute Walk Test in Systemic Sclerosis: Five Years Evolution

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster I

9:00AM-11:00AM: Abstract Number: 389

S-110483 a New Potent EP4 Receptor Antagonist with Immunomodulatory and Analgesic Activities

Rheumatoid Arthritis – Animal Models Poster I

9:00AM-11:00AM: Abstract Number: 390

S-110483, a Novel and Selective EP4 Receptor Antagonist with Anti-Bone Destruction Activities

Rheumatoid Arthritis – Animal Models Poster I

9:00AM-11:00AM: Abstract Number: 612

Safety and Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis over a 6 Month Period

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

9:00AM-11:00AM: Abstract Number: 725

Safety and Efficacy of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc) Subjects Treated in an Open-Label Extension of Trial JBT101-SSc-001

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster I

9:00AM-11:00AM: Abstract Number: 620

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open‑Label, Long-Term Extension Study

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

9:00AM-11:00AM: Abstract Number: 778

Safety Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations

Vasculitis Poster I: Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 322

Safety of Denosumab in a Monocentric Cohort of Kidney Transplant Recipients

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].